Home » Stocks » AgeX Therapeutics

AgeX Therapeutics, Inc. (AGE)

Stock Price: $0.890 USD -0.010 (-1.12%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 33.51M
Revenue (ttm) 1.86M
Net Income (ttm) -12.21M
Shares Out 37.66M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $0.890
Previous Close $0.900
Change ($) -0.010
Change (%) -1.12%
Day's Open 0.910
Day's Range 0.881 - 0.930
Day's Volume 175,183
52-Week Range 0.666 - 3.370

More Stats

Market Cap 33.51M
Enterprise Value 35.14M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 37.66M
Float 31.73M
EPS (basic) -0.33
EPS (diluted) -0.32
FCF / Share -0.27
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.13M
Short Ratio 2.75
Short % of Float 10.04%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 18.07
PB Ratio 12.96
Revenue 1.86M
Operating Income -12.63M
Net Income -12.21M
Free Cash Flow -10.25M
Net Cash -1.62M
Net Cash / Share -0.04
Gross Margin 80.00%
Operating Margin -680.97%
Profit Margin -658.10%
FCF Margin -552.45%
ROA -90.68%
ROE -256.84%
ROIC -5,914.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth23.78%-0.57%-15.73%-
Gross Profit1.481.031.241.36
Operating Income-12.56-11.25-6.66-12.74
Net Income-12.15-7.50-6.58-15.49
Shares Outstanding37.2734.9130.6428.80
Earnings Per Share-0.33-0.21-0.21-0.54
Operating Cash Flow-10.16-8.00-6.29-8.43
Capital Expenditures-0.64-0.02--0.02
Free Cash Flow-10.80-8.02-6.29-8.45
Cash & Equivalents2.356.717.380.26
Total Debt1.96---
Net Cash / Debt0.406.717.380.26
Book Value2.227.457.28-23.42
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AgeX Therapeutics, Inc.
Country United States
Employees 17
CEO Michael D. West

Stock Information

Ticker Symbol AGE
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: AGE
IPO Date November 29, 2018


AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.